Main Conference - Day 3 (May 14)
6:45am - 7:45am60 mins
Sunrise Yoga
Sunrise Yoga: Wellness Event - Reservation Required
7:15am - 7:45am30 mins
Registration
Registration
Breakfast Spotlight Presentations
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 1
LNP-production for mRNA-vaccines, Therapeutics and for Gene-editing - Proof of Concept for a Versatile Process
- Thomas Vrucina - Deputy Head Liposome Technology, Polymun Scientific
Case Studies of Preclinical and Clinical Oligonucleotides in Development
8:25am - 8:30am5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairwoman’s Remarks
8:25am - 8:30am5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairman’s Remarks
- Seb Caille, PhD - Senior Director, Avidity Biosciences
8:25am - 8:30am5 mins
Peptide Discovery to CMC
Co-Chairs' Remarks
- Matteo Villain, PhD - Vice President of Peptide and Oligonucleotide, Veranova
- Marc Jacob, PhD - Head of Strategic Development, Chromatography Products, YMC America
8:25am - 8:30am5 mins
mRNA & Genome Editing: Technology & Applications
Chairman's Remarks
8:25am - 8:30am5 mins
Delivery of Macromolecules
Chairwoman’s Remarks
- Elissa Hobert, PhD - Director of Discovery Technologies, NewCo
8:30am - 9:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
SpiNA siRNA Design Enables Durable Silencing of Inhbe RNA and Fat Loss without Muscle Loss in a Mouse Model of Obesity
- Chandra Vargeese, PhD - Chief Technology Officer, Wave Life Science
8:30am - 9:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Controlling Phosphorothioate Stereochemistry: Challenges and Innovations in Oligonucleotide Manufacturing
- Stefan Lutz, PhD - Chief Scientific Officer, Codexis
8:30am - 9:00am30 mins
Peptide Discovery to CMC
Chemically Convergent Peptide Synthesis: Eliminating SPPS and the Impact on Registered Starting Material Designations
- Kevin Seibert, PhD - Vice President, Engineering, Synthetic Molecule Design and Development, Eli Lilly and Company
8:30am - 9:00am30 mins
mRNA & Genome Editing: Technology & Applications
Physicochemical and Functional Assessment of messenger RNA 5′Cap-end Impurities Under Forced Degradation Conditions
- Eivor Örnskov, Ph.D. - Principal Scientist, Pharmaceutical Sciences, AstraZeneca Gothenburg
8:30am - 9:00am30 mins
Delivery of Macromolecules
Novel Extrahepatic RNAi Therapeutics for Obesity Targeting Adipocytes and Skeletal Muscle via the LEAD™ Technology
- Marc Abrams, PhD - Chief Technology Officer & Head, US Operations, SanegeneBio
9:00am - 9:30am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Precision RNA Editing at Scale: Platform Innovations Generating Product Candidates
- Loic Vincent, PhD - Chief Scientific Officer, Korro Bio
9:00am - 9:30am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Oligonucleotide CMC Case Study
9:00am - 9:30am30 mins
Peptide Discovery to CMC
Peptide CMC Case Study
9:00am - 9:30am30 mins
mRNA & Genome Editing: Technology & Applications
Characterization of mRNA Using Liquid Chromatography and Mass Spectrometry
- Mark Dickman - Professor, University of Sheffield
9:00am - 9:30am30 mins
Delivery of Macromolecules
The Strike Platform Enables Kidney-Selective Gene Silencing
- Mangala Soundar - VP Biology, Judo Bio
9:30am - 10:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Oleic Acid Conjugation as a Brain Shuttle to Reach Nervous System after IV Injection
- Beatriz Llamusi, PhD - Chief Scientific Officer & Co-Founder, Arthex Biotech
9:30am - 10:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Oligonucleotide CMC Case Study
9:30am - 10:00am30 mins
Peptide Discovery to CMC
Development of a Multi-Enzyme Cascade En-Route to Enlicitide (MK-0616)
- Levi Knippel, Ph.D - Senior Scientist, Merck
9:30am - 10:00am30 mins
mRNA & Genome Editing: Technology & Applications
Direct RNA Sequencing to Study mRNA Therapeutics and Their Metabolism
- Andrzej Dziembowski - Head of the Laboratory of RNA Biology, Int'l Institute of Molecular & Cell Biology
9:30am - 10:00am30 mins
Delivery of Macromolecules
siRNA CNS Delivery Using Peptide Ligands and Preclinical Development
- Lucas Siow - CEO and Co-Founder, ProteinQure
10:00am - 10:45am45 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break
10:10am - 10:30am20 mins
TIDES Talks in Poster and Exhibit Hall
Enabling the Scale-Up of Custom Nucleic Acid Chemistries from Development to Commercial Supply
- Christoph Schmoelzer - Head of Product Management, Advanced Therapies, Thermo Fisher Scientific
10:45am - 11:15am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Targeting Noncoding Regulatory RNAs with Antisense Oligonucleotides to Increase Gene Expression for the Potential Treatment of Haploinsufficient Diseases
- Dan Tardiff, PhD - Chief Scientific Officer, CAMP4 Therapeutics
10:45am - 11:15am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Presentation Title TBA
10:45am - 11:15am30 mins
Peptide Discovery to CMC
GLP-1 API Manufacturing Under Pressure: Starting-Material and CDMO Challenges for Emerging Biotechs
- Pin-Nan Cheng, Ph.D - Sr Dir, Drug Substance Development, CMC, Altimmune
10:45am - 11:15am30 mins
mRNA & Genome Editing: Technology & Applications
Sequencing-Based Analytics for the Next Generation of mRNA Therapeutics
- Wayne Doyle - Head of Platform, Eclipse Bioinnovations
10:45am - 11:15am30 mins
Delivery of Macromolecules
Amphiphilic Shuttle Peptide Enables the Development of PMO-based Therapeutics to Treat Basal Cell Carcinoma and Muco-obstructive Lung Diseases
- David Guay, PhD - VP Innovation & Technology, Feldan Therapeutics
11:15am - 11:45am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Targeted Delivery of Oligonucleotides to Different Tissues
- Jim Weterings, PhD - Vice President , Head of Oligonucleotide Therapeutics, Bonito Biosciences
11:15am - 11:45am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
CMC Perspectives and Lessons Learned from TAC-001
- Mark Karmarz, Ph.D - Executive Director of Biologics Development, Tallac Therapeutics
11:15am - 11:45am30 mins
Peptide Discovery to CMC
Peptide CMC Case Study
11:15am - 11:45am30 mins
mRNA & Genome Editing: Technology & Applications
Late Breaking Presentation
11:15am - 11:45am30 mins
Delivery of Macromolecules
Delivering RNAi to Extra-hepatic Tissues
- Punit Seth, PhD - SVP, Research, Alnylam Pharmaceuticals
11:45am - 12:15pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Latest Updates from ANQUR, QurAlis’ Phase 1 Study of QRL-201 for Treatment of ALS
- Hagen Cramer, PhD - Chief Technology Officer, QurAlis
11:45am - 12:15pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Late Breaking Presentation
11:45am - 12:15pm30 mins
Peptide Discovery to CMC
Comprehensive Characterization of Peptides and New Modalities Using Multidimensional Chromatography and Mass Spectrometry
- C. J. Venkatramani, PhD - Distinguished Scientist, Genentech
11:45am - 12:15pm30 mins
mRNA & Genome Editing: Technology & Applications
Late Breaking Presentation
11:45am - 12:15pm30 mins
Delivery of Macromolecules
Discovery and Translation of Extrahepatic Peptides for Oligonucleotide Delivery
- Uyanga Tsedev - Founder & Chief Scientific Officer, Gensaic
12:15pm - 12:20pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Peptide Discovery to CMC
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
mRNA & Genome Editing: Technology & Applications
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Delivery of Macromolecules
Transition to Spotlight Presentation Rooms
12:20pm - 12:50pm30 mins
Spotlight Presentation 1
Tagging the Future: Scalable Biopolymer Production in Solution
- Matteo Villain, PhD - Vice President of Peptide and Oligonucleotide, Veranova
12:20pm - 12:50pm30 mins
Spotlight Presentation 4
Revolutionizing Gene Therapy through Non-Viral, Tissue-Selective Delivery Platforms
- Joo-Sung Yang - VP and Head of the New Therapeutics Business Development, Samyang Biopharm
12:20pm - 12:50pm30 mins
Spotlight Presentation 5
Efficient Conformational Sampling in Nucleic Acids Using LowModeMD
- Alain Deschênes - Vice President, Chemical Computing Group
12:50pm - 1:55pm65 mins
Networking Luncheon in Poster and Exhibit Hall
Networking Luncheon with Last Chance for Poster & Exhibit Viewing
1:10pm - 1:20pm10 mins
TIDES Talks in Poster and Exhibit Hall
OmniAb TIDES Talk
1:55pm - 2:00pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks
1:55pm - 2:00pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairwoman’s Remarks
- Lori Troup - Director of Analytical Development, Dicerna/Novo Nordisk
1:55pm - 2:00pm5 mins
Peptide Discovery to CMC
Chairman's Remarks
- Gary Musso, PhD - President, Musso and Associates LLC
1:55pm - 2:00pm5 mins
mRNA & Genome Editing: Technology & Applications
Chairman’s Remark's
- Frank DeRosa, PhD - Chief Technology Officer & Global Head of Research, mRNA Center of Excellence, Sanofi
- Eckhard Jankowsky, PhD - mRNA Scientist, NewCo
2:00pm - 2:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Development of an Anti-microRNA Therapy for the Treatment of Myotonic Dystrophy Type 1 - The ArthemiR Clinical Trial
- Judy Walker, PhD - Chief Medical Officer, Arthex Biotech
2:00pm - 2:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Regulatory Expectations for Synthetic Oligonucleotides: Trends, Challenges, and Opportunities
- Katharine (Katie) Duncan, PhD - Director, CMC Policy and Advocacy, GlaxoSmithKline (GSK)
2:00pm - 2:30pm30 mins
Peptide Discovery to CMC
Structure-Based Design of Orally Bioavailable Macrocyclic Cyclin A/B RxL Inhibitors
- Andrew Bockus - Director of Chemistry, Circle Pharma, Inc
2:00pm - 2:30pm30 mins
mRNA & Genome Editing: Technology & Applications
mRNA Cancer Vaccines
- Kristine McKinney, Ph.D - Vice President and Head, Cancer Vaccines Research, Moderna
2:30pm - 3:00pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
2:30pm - 3:00pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Practical Application of Platform Approaches for Oligonucleotides
- Jennifer Franklin - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
2:30pm - 3:00pm30 mins
Peptide Discovery to CMC
Oral Delivery of Peptides
- Mridula Dogra, PhD - Director, Eli Lilly and Company
2:30pm - 3:00pm30 mins
mRNA & Genome Editing: Technology & Applications
Late Breaking Presentation
3:00pm - 3:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
First-in-Class Oligonucleotide Therapy against Metastatic Cancer
- Zdravka Medarova, PhD - Co-Founder and Chief Scientific Officer, TransCode Therapeutics
3:00pm - 3:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Application of Accelerated Predictive Stability to siRNA Long Term Stability Assessment
- Zhichao Zhang, Ph.D - Advisor, Bioproduct Research and Development, Eli Lilly & Company
- Shayak Samaddar, Ph.D - Senior Advisor, Drug Product Formulation, Eli Lilly & Company
3:00pm - 3:30pm30 mins
Peptide Discovery to CMC
Building Robust Control Strategies for Peptide APIs: From Synthesis to Regulatory Approval
- Fouad Atouf, PhD - Executive Vice President, and Chief Science Officer, US Pharmacopeia
3:30pm - 4:00pm30 mins
Networking Refreshment Break
4:00pm - 4:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
4:00pm - 4:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
A Risk-Based Framework for Microbiological Control in Oligonucleotide Drug Substance Manufacturing
- Bharath Venkatram - Senior Engineer, Process Development & Scale Up Lab, Amgen
4:00pm - 4:30pm30 mins
Peptide Discovery to CMC
Advancing Sustainable Peptide Synthesis: Replacing Trifluoroacetic Acid in Global Deprotection
- Fernando Albericio, Ph.D - Research Professor, University of Kwazulu-Natal
4:00pm - 4:30pm30 mins
mRNA & Genome Editing: Technology & Applications
Immune-Modulating NanoBiologics (INBs): A Novel mRNA-Based Therapeutic Strategy for the treatment of Autoimmune and Autoinflammatory Diseases - A Preclinical Case Study
- Oron Yacoby Zevi - Chief Scientific Officer, Immunobel Therapeutics
4:30pm - 5:00pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
4:30pm - 5:00pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Ensuring Diastereomeric Consistency in Phosphorothioate-modified siRNAs: Analytical and Process Strategies for Robust Clinical Development
- Joanna Hemming Taylor, PhD - Associate Principal Scientist, AstraZeneca
4:30pm - 5:00pm30 mins
Peptide Discovery to CMC
Terminal Sterilization Strategies for Peptides
- Gary Musso, PhD - President, Musso and Associates LLC
4:30pm - 5:00pm30 mins
mRNA & Genome Editing: Technology & Applications
In Vivo Transient Programming of T Cells with Targeted Nanoparticles Encapsulating eRNATM-encoded hCD19 CAR Achieves Deep Depletion of B cells in Blood and Lymphoid Tissues
- Viorel Simion, Ph.D - Director of Immunology, Sail Biomedicines
5:00pm - 5:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
5:00pm - 5:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Development of a HILIC-WAX Two-Dimensional Liquid Chromatography Method for UV-Based Quantitation of Antisense Oligonucleotide Impurities
- Xiao Zhou - Senior Scientist, Biogen
5:00pm - 5:30pm30 mins
Peptide Discovery to CMC
Developing Analytical Control Strategies for Complex Synthetic Peptides: A Lifecycle-Focused, Regulatory-Aligned Approach
- Lin Wang, PhD - Director, Analytical CMC, Gilead Sciences
5:00pm - 5:30pm30 mins
mRNA & Genome Editing: Technology & Applications
Late Breaking Presentation
5:30pm - 6:00pm30 mins
mRNA & Genome Editing: Technology & Applications
Beyond the Needle: Engineering Novel mRNA Lipid Nanoparticle Formulations for Mucosal Vaccination
- Neha Kaushal, Ph.D - Associate Director, Research and Biomarkers, Sanofi mRNA Center of Excellence
6:00pm - 6:05pm5 mins
Close of TIDES 2026
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.